Meet Kindeva Hollow Microstructured Transdermal System

Powerful cancer vaccines are one part of the cancer treatment puzzle. Kindeva Hollow Microstructured Transdermal System (hMTS) is designed to help your vaccine reach its treatment potential through intradermal delivery. It’s time to approach clinical trials with confidence.

Better delivery, better device

Why intradermal delivery?
- Potential for enhanced immune response

Why Kindeva hMTS?
- Easy, consistent, reproducible intradermal delivery
- Higher volumes vs. other intradermal delivery devices

Now actively supporting programs through Phase IIa.
Patient-friendly technology made to scale

Kindeva Hollow Microstructured Transdermal System (hMTS) offers patient-friendly design based on voice-of-customer research. Let us help bring your life-saving therapy to market – from concept to commercialization.

Why Kindeva Drug Delivery?

- Over 50 years’ experience working with challenging drug formulations
- Able to advise through early-, mid- and late-stage development

Proprietary technology

Kindeva hMTS can offer reproducible intradermal delivery thanks to sound science. Proprietary microreplication technology is used for hollow microneedle array molding and production.

In addition to hMTS, our Solid Microstructured Transdermal Structures are suitable for delivering:

- Other Vaccines
- Therapeutic Peptides
- Small Molecules
- Other Potent Biologics

Product details

- Doses from 0.5 mL to 2 mL
- Compatible with many viscosities
- Wear time within minutes*
- 1 cm array molded from medical-grade polymer
- Needle length: 1500µm

Product in development. Not available for commercial sale.

* depending on volume and formulation